JP2012211150A5 - - Google Patents

Download PDF

Info

Publication number
JP2012211150A5
JP2012211150A5 JP2012128597A JP2012128597A JP2012211150A5 JP 2012211150 A5 JP2012211150 A5 JP 2012211150A5 JP 2012128597 A JP2012128597 A JP 2012128597A JP 2012128597 A JP2012128597 A JP 2012128597A JP 2012211150 A5 JP2012211150 A5 JP 2012211150A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
liquid pharmaceutical
botulinum neurotoxin
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012128597A
Other languages
English (en)
Japanese (ja)
Other versions
JP5662379B2 (ja
JP2012211150A (ja
Filing date
Publication date
Priority claimed from GB0415491A external-priority patent/GB2416122A/en
Application filed filed Critical
Publication of JP2012211150A publication Critical patent/JP2012211150A/ja
Publication of JP2012211150A5 publication Critical patent/JP2012211150A5/ja
Application granted granted Critical
Publication of JP5662379B2 publication Critical patent/JP5662379B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012128597A 2004-07-12 2012-06-06 ボツリヌス神経毒を含む医薬組成物 Expired - Lifetime JP5662379B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0415491.0 2004-07-12
GB0415491A GB2416122A (en) 2004-07-12 2004-07-12 Botulinum neurotoxin composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007520876A Division JP5301830B2 (ja) 2004-07-12 2005-07-06 ボツリヌス神経毒を含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2012211150A JP2012211150A (ja) 2012-11-01
JP2012211150A5 true JP2012211150A5 (cg-RX-API-DMAC7.html) 2014-08-21
JP5662379B2 JP5662379B2 (ja) 2015-01-28

Family

ID=32865775

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007520876A Expired - Lifetime JP5301830B2 (ja) 2004-07-12 2005-07-06 ボツリヌス神経毒を含む医薬組成物
JP2012128597A Expired - Lifetime JP5662379B2 (ja) 2004-07-12 2012-06-06 ボツリヌス神経毒を含む医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007520876A Expired - Lifetime JP5301830B2 (ja) 2004-07-12 2005-07-06 ボツリヌス神経毒を含む医薬組成物

Country Status (19)

Country Link
US (4) US9125804B2 (cg-RX-API-DMAC7.html)
EP (4) EP1817051B2 (cg-RX-API-DMAC7.html)
JP (2) JP5301830B2 (cg-RX-API-DMAC7.html)
CN (2) CN1984675B (cg-RX-API-DMAC7.html)
AR (2) AR049978A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0513327B8 (cg-RX-API-DMAC7.html)
CA (1) CA2572915C (cg-RX-API-DMAC7.html)
DK (3) DK1817051T4 (cg-RX-API-DMAC7.html)
ES (3) ES2537312T5 (cg-RX-API-DMAC7.html)
FI (1) FI1817051T4 (cg-RX-API-DMAC7.html)
GB (1) GB2416122A (cg-RX-API-DMAC7.html)
HU (2) HUE043301T2 (cg-RX-API-DMAC7.html)
IL (1) IL180380A (cg-RX-API-DMAC7.html)
MX (1) MX2007000409A (cg-RX-API-DMAC7.html)
PL (3) PL1817051T5 (cg-RX-API-DMAC7.html)
PT (3) PT2939688T (cg-RX-API-DMAC7.html)
RU (1) RU2407541C2 (cg-RX-API-DMAC7.html)
TR (1) TR201906275T4 (cg-RX-API-DMAC7.html)
WO (1) WO2006005910A2 (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
WO2005120546A2 (en) 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
KR101430767B1 (ko) 2005-07-18 2014-08-19 유니버시티 오브 메사츄세츠 로웰 나노에멀젼 조성물 및 이의 제조 및 사용 방법
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
AU2016204034B2 (en) * 2005-10-06 2017-12-21 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
CN103919690B (zh) 2005-12-01 2020-07-31 麻萨诸塞州洛厄尔大学 肉毒杆菌纳米乳液
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
SG10201607909WA (en) 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008070538A2 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
JP5259710B2 (ja) 2007-07-10 2013-08-07 メディ‐トックス、インク． ボツリヌス毒素の安定性が改善された薬学的液状組成物
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
CA2726836C (en) * 2008-06-26 2019-06-18 Anterios, Inc. Use of nanoemulsions in the manufacture of a medicament for treating skin disorders
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
KR20110106346A (ko) * 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
KR102005930B1 (ko) 2008-12-31 2019-07-31 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
CA2766521C (en) * 2009-06-25 2020-07-21 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
JP5990176B2 (ja) 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
MX355771B (es) * 2011-03-31 2018-04-30 Medy Tox Inc Preparacion liofilizada de toxinas de botulismo.
US9498521B2 (en) * 2011-09-28 2016-11-22 Wisconsin Alumni Research Foundation Purification, characterization, and use of Clostridium botulinum neurotoxin BoNT/A3
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
JP2015534814A (ja) * 2012-10-31 2015-12-07 イプセン バイオイノベーション リミテッド 組換えクロストリジウムボツリヌス神経毒
MX377653B (es) 2013-03-15 2025-03-11 Orpro Therapeutics Inc Producto y uso para normalización de la viscoelasticidad del moco.
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
RU2593344C2 (ru) * 2014-03-05 2016-08-10 Михаил Григорьевич Сойхер Способ лечения бруксизма
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
WO2016102068A1 (en) 2014-12-23 2016-06-30 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
AU2015381351B2 (en) * 2015-02-03 2020-05-14 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
RU2018119765A (ru) 2015-10-29 2019-12-02 Реванс Терапьютикс, Инк. Инъекционные препараты на основе ботулотоксина и способы их применения, обеспечивающие длительное терапевтическое и косметического действие
WO2017177160A1 (en) 2016-04-07 2017-10-12 Nevakar Llc Formulation for use in a method of treatment of pain
UA123679C2 (uk) 2016-05-27 2021-05-12 Іпсен Біофарм Лімітед Рідка композиція нейротоксину, стабілізована триптофаном або тирозином
RU2651044C2 (ru) * 2016-08-22 2018-04-18 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. ак. Е.Н. Мешалкина" Минздрава России) Способ лечения желудочковых нарушений ритма сердца (варианты)
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
US10369190B2 (en) 2016-09-13 2019-08-06 Allergan, Inc. Non-protein clostridial toxin compositions
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
KR101744900B1 (ko) * 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
HRP20250319T1 (hr) 2017-02-16 2025-05-09 Sonnet BioTherapeutics, Inc. Fuzijski proteini s domenom za vezanje na albumin
CN111432882A (zh) * 2017-10-03 2020-07-17 内瓦卡公司 对乙酰氨基酚-普瑞巴林组合和治疗疼痛的方法
WO2019113044A1 (en) * 2017-12-07 2019-06-13 Ps Therapies Ltd Topical compositions and methods of use thereof
IL285634B2 (en) 2019-02-21 2025-06-01 Merz Pharma Gmbh Co Kgaa Novel uses of botulinum neurotoxin for the treatment of tremor
RU2728102C1 (ru) * 2019-12-19 2020-07-28 Александр Александрович Ильин Способ лечения гипертонуса латеральной крыловидной мышцы
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
CA3202665A1 (en) * 2020-12-18 2022-06-23 Sung Su Jang Pharmaceutical composition for long-term storage of liquid formulation of botulinum toxin
CN119258202A (zh) * 2023-07-05 2025-01-07 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物及其应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
EP0627924B1 (en) 1992-10-02 2000-12-27 Genetics Institute, Inc. Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
AU2340299A (en) † 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
CA2400318C (en) * 2000-02-08 2005-06-14 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020197278A1 (en) * 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
RU2206337C1 (ru) * 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Лекарственный препарат для лечения мышечных дистоний и способ его получения
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
WO2006013370A1 (en) 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
ES2627627T3 (es) * 2004-08-04 2017-07-28 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina botulínica A2
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2012211150A5 (cg-RX-API-DMAC7.html)
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
JP2017516848A5 (cg-RX-API-DMAC7.html)
JP2017516847A5 (cg-RX-API-DMAC7.html)
IL259921A (en) A new stabilizing factor for pharmaceutical proteins
WO2015044292A8 (en) Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
MX2012002861A (es) Formulaciones farmaceuticas muy concentradas.
JP2016065060A5 (cg-RX-API-DMAC7.html)
JP2013505270A5 (cg-RX-API-DMAC7.html)
FI2504353T4 (fi) Lipopeptidikoostumukset ja vastaavat menetelmät
JP2013543505A5 (cg-RX-API-DMAC7.html)
AR081679A1 (es) Metodos y composiciones para la administracion intratecal de heparan n-sulfatasa, envase
RU2008148830A (ru) Препарат вакцины на основе конъюгата никотин-носитель
JP2019509311A5 (cg-RX-API-DMAC7.html)
NZ725360A (en) Liquid pharmaceutical composition
HRP20201242T1 (hr) Tekući farmaceutski pripravak
BR112016006455A2 (pt) ?formulação de conjugado de hormônio de crescimento humano de ação prolongada?
JP2014516515A5 (cg-RX-API-DMAC7.html)
CU20170176A7 (es) Composición farmacéutica que comprende péptido tipo apl
CN104507495A (zh) 轮状病毒疫苗组合物及其制备方法
FI3554474T3 (fi) Mikafungiinikoostumuksia
AR086672A1 (es) Formulaciones de furina recombinante
JP2014519506A5 (cg-RX-API-DMAC7.html)
CR20200240A (es) Formulación farmacéutica estable de una proteína de fusión
TH138064A (th) สูตรตำรับแอนทิบอดีแอนทิ-her2 ใต้หนัง